$ARQT
Arcutis Biotherapeutics Inc Stock $arqt

$arqt Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000178730624000153 Filed on November 06, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q4
Revenue		$44.76M	$13.53M
YoY Change		17.44%	356.81%
Cost Of Revenue		$5.503M	$2.246M
YoY Change		366.36%	363.09%
Gross Profit		$39.25M	$11.28M
YoY Change		6.29%	355.57%
Gross Profit Margin		87.7%	83.39%
Selling, General & Admin		$58.82M	$48.67M
YoY Change		23.58%	31.47%
% of Gross Profit		149.84%	431.51%
Research & Development		$19.50M	$23.78M
YoY Change		-25.67%	-29.82%
% of Gross Profit		49.68%	210.77%
Depreciation & Amortization		$1.432M	$385.0K
YoY Change		616.0%	10.95%
% of Gross Profit		3.65%	3.41%
Operating Expenses		$78.32M	$72.45M
YoY Change		4.41%	2.18%
Operating Profit		-$39.07M	-$61.17M
YoY Change		5.86%	-10.6%
Interest Expense		-$6.653M	-$7.762M
YoY Change		-188.01%	12.25%
% of Operating Profit
Other Income/Expense, Net		$4.182M	$2.672M
YoY Change		53.69%	-19.52%
Pretax Income		-$41.54M	-$66.26M
YoY Change		-0.49%	-8.0%
Income Tax		$0.00	$25.00K
% Of Pretax Income
Net Earnings		-$41.54M	-$66.28M
YoY Change		-7.21%	-7.96%
Net Earnings / Revenue		-92.81%	-490.05%
Basic Earnings Per Share		-$0.33
Diluted Earnings Per Share		-$0.33	-$0.71
COMMON SHARES
Basic Shares Outstanding	117.0M shares	116.9M shares	94.38M shares
Diluted Shares Outstanding		124.3M shares

Balance Sheet

Concept	2024 Q3	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$330.6M	$271.9M
YoY Change	45.55%	-33.63%
Cash & Equivalents	$134.9M	$88.40M
Short-Term Investments	$195.7M	$183.5M
Other Short-Term Assets	$19.03M	$19.63M
YoY Change	-9.83%	65.72%
Inventory	$14.02M	$13.13M
Prepaid Expenses
Receivables	$60.12M	$25.81M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$423.7M	$330.4M
YoY Change	50.5%	-24.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.186M	$1.539M
YoY Change	-31.64%	-18.18%
Goodwill
YoY Change
Intangibles	$9.792M	$6.438M
YoY Change	47.8%	-10.43%
Long-Term Investments
YoY Change
Other Assets	$596.0K	$596.0K
YoY Change	0.0%	664.1%
Total Long-Term Assets	$13.63M	$10.93M
YoY Change	19.48%	-7.87%
TOTAL ASSETS
Total Short-Term Assets	$423.7M	$330.4M
Total Long-Term Assets	$13.63M	$10.93M
Total Assets	$437.4M	$341.4M
YoY Change	49.29%	-24.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.33M	$11.99M
YoY Change	46.63%	35.86%
Accrued Expenses	$52.79M	$33.94M
YoY Change	88.57%	19.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$99.51M	$0.00
YoY Change
Total Short-Term Liabilities	$172.4M	$46.67M
YoY Change	311.63%	23.44%
LONG-TERM LIABILITIES
Long-Term Debt	$105.1M	$201.8M
YoY Change	-47.66%	2.04%
Other Long-Term Liabilities	$420.0K	$849.0K
YoY Change	-88.33%
Total Long-Term Liabilities	$105.5M	$202.6M
YoY Change	-47.45%	2.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$172.4M	$46.67M
Total Long-Term Liabilities	$105.5M	$202.6M
Total Liabilities	$280.7M	$252.7M
YoY Change	14.0%	5.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.111B	-$981.9M
YoY Change	21.36%	36.41%
Common Stock	$12.00K	$9.000K
YoY Change	100.0%	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$156.6M	$88.67M
YoY Change
Total Liabilities & Shareholders Equity	$437.4M	$341.4M
YoY Change	49.29%	-24.02%

Cashflow Statement

Concept	2024 Q3	2023 Q4
OPERATING ACTIVITIES
Net Income	-$41.54M	-$66.28M
YoY Change	-7.21%	-7.96%
Depreciation, Depletion And Amortization	$1.432M	$385.0K
YoY Change	616.0%	10.95%
Cash From Operating Activities	-$34.69M	-$56.24M
YoY Change	-21.13%	-20.86%
INVESTING ACTIVITIES
Capital Expenditures	$143.0K	$6.000K
YoY Change	138.33%	-95.12%
Acquisitions
YoY Change
Other Investing Activities	$84.92M	-$62.18M
YoY Change	86.19%	-246.91%
Cash From Investing Activities	$84.78M	-$62.19M
YoY Change	86.12%	-247.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	394.0K	99.29M
YoY Change	-54.19%	10221.1%
NET CHANGE
Cash From Operating Activities	-34.69M	-56.24M
Cash From Investing Activities	84.78M	-62.19M
Cash From Financing Activities	394.0K	99.29M
Net Change In Cash	50.48M	-19.14M
YoY Change	1977.49%	-31.4%
FREE CASH FLOW
Cash From Operating Activities	-$34.69M	-$56.24M
Capital Expenditures	$143.0K	$6.000K
Free Cash Flow	-$34.83M	-$56.25M
YoY Change	-20.91%	-20.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001787306
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3027 Townsgate Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Westlake Village
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91361
	dei	City Area Code CityAreaCode	805
	dei	Local Phone Number LocalPhoneNumber	418-5006
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	617000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	925000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	195710000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25807000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	14015000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	13134000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18408000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18704000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	423720000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	330431000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1186000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1539000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9792000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	100000	usd
CY2023Q1	arqt	Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises	0	usd
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	183463000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	60119000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6438000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2060000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2361000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	596000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	596000	usd
CY2024Q3	us-gaap	Assets Assets	437354000	usd
CY2023Q4	us-gaap	Assets Assets	341365000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	19325000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11992000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33941000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61727278	shares
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	649000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12523000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	209581000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-195856000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4089000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	9951000	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1782000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	486000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	8144000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2697000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	14015000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	13134000	usd
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	739000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	864000	usd
CY2024Q3	arqt	Prepaid Clinical Trial Test Costs Current PrepaidClinicalTrialTestCostsCurrent	0	usd
CY2023Q4	arqt	Prepaid Clinical Trial Test Costs Current PrepaidClinicalTrialTestCostsCurrent	1024000	usd
CY2024Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8734000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8208000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18408000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18704000	usd
CY2024Q3	arqt	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	292000	usd
CY2023Q4	arqt	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	4192000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6833000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3299000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	52790000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33941000	usd
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	us-gaap	Operating Income Loss OperatingIncomeLoss	-179932000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13455000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9114000	usd
CY2023Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-41742000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-128927000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-41537000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-80100000	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	ARCUTIS BIOTHERAPEUTICS, INC.
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	134851000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	88398000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	52790000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	116998829	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	116998829	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8109000	usd
CY2024Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	usd
CY2023Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	30000000	usd
CY2024Q3	us-gaap	Revenues Revenues	44755000	usd
CY2023Q3	us-gaap	Revenues Revenues	38109000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5503000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1182000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19501000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26236000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	47595000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	83821000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	75013000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-39066000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-36904000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4182000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2721000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	6653000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	7559000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-44765000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	56000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-57000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	827000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	108000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40710000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119627687	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	119627687	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-2974255
	dei	Trading Symbol TradingSymbol	ARQT
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	117044591	shares
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	99513000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	798000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	735000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	172426000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46668000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2772000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3382000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	105095000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	201799000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	420000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	849000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	280713000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	252698000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96787343	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96787343	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1267251000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1070558000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	533000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1111155000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-981904000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	156641000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	88667000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	437354000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	341365000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	44755000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	97182000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	15660000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	28000000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	30420000	usd
	us-gaap	Revenues Revenues	125182000	usd
	us-gaap	Revenues Revenues	46080000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12223000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2741000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61940000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	86800000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	58817000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	171784000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	136471000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	245947000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	226012000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-120765000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	21617000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	21950000	usd
CY2024Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-41537000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-192768000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3023000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	324000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3088000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-129251000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-195856000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	771000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	165000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	528000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1017000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-115000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	529000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	902000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44657000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-128722000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-194954000	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.19
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	124302317	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	124302317	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61727278	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61462025	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61462025	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	88667000	usd
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	10820000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	161682000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	82000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10030000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-116000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-21000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35382000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	224942000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	806000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-127000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-34000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-52332000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	186427000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	394000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10530000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	771000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	56000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-41537000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	156641000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9479000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	724000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-52000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	139732000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	74000	usd
CY2023Q2	arqt	Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises	0	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	993000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10578000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	128000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-6000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-70991000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	80508000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	867000	usd
CY2023Q3	arqt	Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises	0	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9999000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	165000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-57000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-44765000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	46717000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-129251000	usd
	us-gaap	Depreciation Depreciation	495000	usd
	us-gaap	Depreciation Depreciation	573000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	301000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	266000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1646000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	563000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	5805000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	5517000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	2809000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	3014000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	32337000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	30056000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	429000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	33133000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10959000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	135000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6399000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	882000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10087000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2334000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4345000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	18850000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-323000	usd
	arqt	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-547000	usd
	arqt	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-489000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-111410000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-190813000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	237421000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	107660000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	231507000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	350500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	143000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	422000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6057000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	242418000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1282000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1041000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	649000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	993000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	161682000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	163613000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2034000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-118000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	46145000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	53521000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89323000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54875000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135468000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108396000	usd
	arqt	Milestone Payment For Intangible Asset Incurred But Not Yet Paid MilestonePaymentForIntangibleAssetIncurredButNotYetPaid	5000000	usd
	arqt	Milestone Payment For Intangible Asset Incurred But Not Yet Paid MilestonePaymentForIntangibleAssetIncurredButNotYetPaid	0	usd
	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	19253000	usd
	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	18862000	usd
CY2024Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	15789474	shares
CY2024Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.50
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	161700000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1111200000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-981900000	usd
CY2024Q3	arqt	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	331200000	usd
CY2023Q4	arqt	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	272800000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to revenue recognition, accruals for research and development activities, the fair value of derivative liabilities, stock-based compensation expense, and income taxes. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ from those estimates.</span></div>
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	600000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	900000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by either the financial institutions holding its cash or by its customers owing trade receivables to the extent recorded on the condensed consolidated</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span>balance sheets. To manage accounts receivable credit risk, the Company evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses.
CY2024Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	44755000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8109000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	97182000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	15660000	usd
CY2024Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	usd
CY2023Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	30000000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	28000000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	30420000	usd
CY2024Q3	us-gaap	Revenues Revenues	44755000	usd
CY2023Q3	us-gaap	Revenues Revenues	38109000	usd
	us-gaap	Revenues Revenues	125182000	usd
	us-gaap	Revenues Revenues	46080000	usd
CY2024Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	330561000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	271861000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134851000	usd
CY2024Q3	arqt	Cash And Cash Equivalents Unrealized Gain CashAndCashEquivalentsUnrealizedGain	0	usd
CY2024Q3	arqt	Cash And Cash Equivalents Unrealized Loss CashAndCashEquivalentsUnrealizedLoss	0	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	134851000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	195082000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	629000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	195710000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88395000	usd
CY2023Q4	arqt	Cash And Cash Equivalents Unrealized Gain CashAndCashEquivalentsUnrealizedGain	3000	usd
CY2023Q4	arqt	Cash And Cash Equivalents Unrealized Loss CashAndCashEquivalentsUnrealizedLoss	0	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	88398000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	183365000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	128000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	30000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	183463000	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P18M
CY2023Q4	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P18M
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	usd
CY2023Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	849000	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	429000	usd
CY2024Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	420000	usd
CY2024Q3	arqt	Prepaid Copay Assistance Program And Rebates PrepaidCopayAssistanceProgramAndRebates	8935000	usd
CY2023Q4	arqt	Prepaid Copay Assistance Program And Rebates PrepaidCopayAssistanceProgramAndRebates	8608000	usd
CY2024Q3	arqt	Accrued Sales Discounts AccruedSalesDiscounts	30029000	usd
CY2023Q4	arqt	Accrued Sales Discounts AccruedSalesDiscounts	11578000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15636000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14872000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	200000000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	200000000	usd
CY2024Q3	arqt	Debt Instrument Accrued Final Fee DebtInstrumentAccruedFinalFee	6970000	usd
CY2023Q4	arqt	Debt Instrument Accrued Final Fee DebtInstrumentAccruedFinalFee	4876000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2362000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3077000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	204608000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	201799000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	99513000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	105095000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	201799000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	213900000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7919699	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.52
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1435000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3677916	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.18
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	307919	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.17
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5346477	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	22.49
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	308725	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	24.44
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5634494	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.51
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y14D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23561000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2120880	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.16
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M20D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	8715000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1700000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1200000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3100000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	22100000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.64
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.76
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10241000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9999000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32337000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30056000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	1700000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12238260	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11229576	shares
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001787306-24-000153-index-headers.html	Edgar Link	pending
0001787306-24-000153-index.html	Edgar Link	pending
0001787306-24-000153.txt	Edgar Link	pending
0001787306-24-000153-xbrl.zip	Edgar Link	pending
arqt-20240930.htm	Edgar Link	pending
arqt-20240930.xsd	Edgar Link	pending
exhibit311ceoq32024.htm	Edgar Link	pending
exhibit312cfoq32024.htm	Edgar Link	pending
exhibit321ceocfoq32024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
arqt-20240930_def.xml	Edgar Link	unprocessable
arqt-20240930_lab.xml	Edgar Link	unprocessable
arqt-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
arqt-20240930_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
arqt-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARQT
Arcutis Biotherapeutics Inc Stock $arqt

2024 Q4 Form 10-Q Financial Statement

#000178730624000153 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARQT Arcutis Biotherapeutics Inc Stock $arqt

2024 Q4 Form 10-Q Financial Statement

#000178730624000153 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARQT
Arcutis Biotherapeutics Inc Stock $arqt